key: cord-0962781-i757oxb6
authors: Hoiland, Ryan L.; Stukas, Sophie; Cooper, Jennifer; Thiara, Sonny; Chen, Luke Y.C.; Biggs, Catherine M.; Hay, Kevin; Lee, Agnes Y.Y.; Shojania, Kamran; Abdulla, Alym; Wellington, Cheryl L.; Sekhon, Mypinder S.
title: Amelioration of COVID‐19 related cytokine storm syndrome: Parallels to chimeric antigen receptor‐T cell cytokine release syndrome
date: 2020-06-25
journal: Br J Haematol
DOI: 10.1111/bjh.16961
sha: 9f4010a6b7072ccf196c0a415f041fcd2a863b73
doc_id: 962781
cord_uid: i757oxb6

Coronavirus disease‐2019 (COVID‐19) severity appears to parallel the host immune response, with a subset of patients developing COVID‐19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID‐19,(2–5) and interleukin (IL)‐6 appears to play a central role in COVID‐19 related CSS.(6–8) Based on the success of IL‐6 receptor blockade for chimeric antigen receptor T‐cell therapy associated cytokine release syndrome (CAR T‐cell CRS), similar strategies using tocilizumab are being investigated in COVID‐19.

Coronavirus disease-2019 (COVID-19) severity appears to parallel the host immune response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS).(1) Serum inflammatory cytokines are elevated in COVID-19, (2) (3) (4) (5) and interleukin (IL)-6 appears to play a central role in COVID-19 related CSS. (6) (7) (8) Based on the success of IL-6 receptor blockade for chimeric antigen receptor T-cell therapy associated cytokine release syndrome (CAR T-cell CRS), similar strategies using tocilizumab are being investigated in COVID-19. However, early reports described only modest elevations of IL-6 of ~50 pg/mL (reference range < 7 pg/mL) in severe COVID-19 (2) (3) (4) 9) compared to IL-6 levels often > 10,000 pg/L in CAR-T cell CRS,(10) leading authors to conclude that COVID-19 pathophysiology is attributable to alternate mechanisms apart from CSS. (11) Two central mechanistic considerations may help resolve this controversy. First, determining if COVID-19 is associated with markedly elevated IL-6, in the range seen in CAR T-cell CRS, is crucial. Second, current trials are focussing mortality and ventilation endpoints but data pertaining to the effect of IL-receptor blockade on inflammatory cytokine levels and cardiorespiratory outcomes are needed to established biologic efficacy. We therefore conducted a preliminary evaluation of tocilizumab on inflammatory cytokines including IL-1β, IL-6, IL-10 and tumor necrosis factor alpha (Figure 2) . Further, mean arterial pressure improved following tocilizumab on days 3 (P=0.042), 4 (P=0.042) and 6 (P=0.041) (Figure   2) , which was reflected in markedly decreased intravenous norepinephrine dose requirements. As of June 2, 2020, four patients (80%) have been discharged home and one (20%) died in ICU.

Our case series provides evidence that patients with severe COVID-19 may exhibit hypercytokinemia, in keeping with ranges described in CAR-T CRS. We further demonstrate reductions in serum inflammatory markers following tocilizumab administration that correlate with Accepted Article improved clinical parameters. Overall, these preliminary findings provide context for the biological plausibility of IL-6 receptor blockade in COVID-19 CSS. While tocilizumab has been used in IL-6 mediated inflammatory conditions such as the CAR-T CRS,(10) investigation of the potential efficacy of tocilizumab for treating COVID-19 to-date has been limited to cohorts that are not critically ill (e.g.

requiring mechanical ventilation(13)). To the best of our knowledge, our case series is the first to demonstrate an association between tocilizumab administration and reductions in multiple key inflammatory cytokines and laboratory variables in the severe spectrum of critically ill COVID-19 patients (requiring invasive mechanical ventilation and VV-ECMO). Importantly, all patients deemed to have COVID-19 CSS had markedly elevated IL-6 levels, as high as 13,140pg/ml, which to our knowledge is one of the highest serum IL-6 values reported in a COVID-19 patient (Figure 1) COVID-19,(3) the median of which is >20-fold lower than that of our patients.

The results of our case series should not used to unequivocally advocate for the use of tocilizumab in COVID-19 but instead provide context to upcoming and emerging trials of IL-6 receptor blockade. Attention should be given to defining COVID-19 CSS and elucidating the

Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical and immunologic features in severe and moderate Coronavirus Disease

Clinical Features of 69 Cases with Coronavirus Disease

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan , China: a retrospective cohort study

Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Facing COVID -19 in the ICU : vascular